| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,867 | -12,276 |
| Stock-based compensation expense | 2,165 | 1,639 |
| Accretion of investment discount | 412 | 314 |
| Amortization of debt issuance costs and discount | 312 | 312 |
| Change in fair value of warrant liability | -4,454 | -5,094 |
| Change in fair value of derivative liability | 0 | 0 |
| Noncash operating lease expense for right-of-use asset | 239 | 156 |
| Prepaid expenses, other assets, deferred costs, and other | -1,745 | -803 |
| License agreement receivable | 9,247 | 9,247 |
| License agreement contract asset | -9,509 | -9,509 |
| Accounts payable | -992 | 1,713 |
| Accrued expenses | -1,019 | -1,316 |
| Deferred revenue | -365 | -652 |
| Other liabilities | -298 | -193 |
| Net cash used in operating activities | -23,684 | -14,960 |
| Purchase of investments | 0 | 0 |
| Maturity of investments | 36,130 | 23,713 |
| Net cash provided by investing activities | 36,130 | 23,713 |
| Proceeds from common stock issued | 4 | - |
| Payment of convertible debt | 14,000 | 14,000 |
| Payment of deferred offering costs | 110 | 110 |
| Proceeds from employee stock purchase plan issuances | 51 | 26 |
| Net cash (used in) provided by financing activities | -14,055 | -14,084 |
| Net decrease in cash, cash equivalents, and restricted cash | -1,609 | -5,331 |
| Cash and cash equivalents at beginning of period | 16,595 | - |
| Cash and cash equivalents at end of period | 14,986 | - |
SCYNEXIS INC (SCYX)
SCYNEXIS INC (SCYX)